Werewolf Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO Werewolf Therapeutics is Dan Hicklin, benoemd in Oct2017, heeft een ambtstermijn van 7.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.37M, bestaande uit 42.7% salaris en 57.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.48% van de aandelen van het bedrijf, ter waarde $ 1.60M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 5.1 jaar.
Belangrijke informatie
Dan Hicklin
Algemeen directeur
US$1.4m
Totale compensatie
| Percentage CEO-salaris | 42.7% |
| Dienstverband CEO | 7.1yrs |
| Eigendom CEO | 1.5% |
| Management gemiddelde ambtstermijn | 3.9yrs |
| Gemiddelde ambtstermijn bestuur | 5.1yrs |
Recente managementupdates
Recent updates
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$42m |
| Dec 31 2023 | US$1m | US$583k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$37m |
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$50m |
| Dec 31 2022 | US$2m | US$530k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$60m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$115m |
| Dec 31 2021 | US$2m | US$498k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$197m |
| Mar 31 2021 | n/a | n/a | -US$127m |
| Dec 31 2020 | US$3m | US$425k | -US$28m |
Compensatie versus markt: De totale vergoeding ($USD 1.37M ) Dan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.78K ).
Compensatie versus inkomsten: De vergoeding van Dan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Dan Hicklin (60 yo)
7.1yrs
Tenure
US$1,366,904
Compensatie
Dr. Daniel J. Hicklin, Ph D., also known as Dan, Founded Werewolf Therapeutics, Inc. in October 2017 and has been its President and Chief Executive Officer since August 2019. He serves on its Board of Dire...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 7.1yrs | US$1.37m | 1.48% $ 1.6m | |
| CFO, Treasurer & Assistant Secretary | 3.8yrs | US$815.59k | 0% $ 0 | |
| Chief Medical Officer | 4yrs | US$855.77k | 0% $ 0 | |
| Senior Vice President of Research | less than a year | geen gegevens | geen gegevens | |
| Chief Technology Officer | 3.4yrs | US$3.86m | geen gegevens | |
| Chief Business Officer | 4.3yrs | geen gegevens | geen gegevens |
3.9yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HOWL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 7.1yrs | US$1.37m | 1.48% $ 1.6m | |
| Independent Chairman of the Board | 7.1yrs | US$104.03k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$78.66k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5yrs | US$62.32k | 0.036% $ 38.5k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board & Director | 6.3yrs | geen gegevens | 0.033% $ 35.8k | |
| Independent Director | 5.3yrs | US$78.53k | 4.68% $ 5.1m | |
| Independent Director | 3.1yrs | US$65.36k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$72.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
5.1yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HOWL wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).